Printer Friendly

UNIGENE AND RUTGERS LAUNCH PROGRAM TO DEVELOP ORAL CALCITONIN

 UNIGENE AND RUTGERS LAUNCH PROGRAM TO DEVELOP ORAL CALCITONIN
 FAIRFIELD, N.J., Nov. 11 /PRNewswire/ -- Unigene Laboratories, Inc. (NASDAQ: UGNE) today announced the execution of two agreements with the Rutgers University College of Pharmacy which will establish a comprehensive program for the development of an oral drug delivery system for calcitonin produced by Unigene's proprietary process.
 In addition to developing their own novel strategies for delivering calcitonin orally, the collaborators will evaluate the applicability of other recently developed systems to assess their effectiveness in delivering calcitonin. The unique advantages afforded by Unigene's production technology should allow the company to ultimately utilize delivery systems which would otherwise be far too expensive for conventional calcitonin producers.
 "We have a distinct advantage over any calcitonin manufacturer in our quest for an oral calcitonin dosage form because our production process reduces the cost of the drug so significantly," commented Ronald S. Levy, vice president of Unigene. "As a result, we can use larger drug payloads to compensate for the lower efficiencies seen in oral delivery systems while still keeping costs under control. Pharmaceutical companies are feeling concerted pressure from both the government and consumers to contain rising prescription drug costs, and our technology can help them achieve that goal."
 Calcitonin, a $1 billion per year drug used primarily for the treatment of osteoporosis, is currently sold either in an injectable formulation or as a nasal spray. Although its combined safety and efficacy profile compares very favorably with any osteoporosis drug, its sales in several countries are substantially less than for some competing drugs with poorer profiles, primarily because those drugs are less expensive and are available in more convenient dosage forms, such as a pill or a patch. It is clear that a major market opportunity exists for a new calcitonin formulation which can be produced cost- effectively.
 The university research team will be headed by Dr. Patrick Sinko, an internationally recognized expert in biopharmaceutics and the oral delivery of peptides and peptide-like drugs. Dr. Sinkos's broad research activities focus on the mechanisms of transport and absorption of small proteins in the gastrointestinal tract.
 The Rutgers College of Pharmacy was a pioneer in the development of transdermal technologies for drug delivery, and it currently maintains a state-of-the-art pharmaceutical processing facility that is supported by 15 major pharmaceutical companies. The college, currently celebrating its centennial year of operation, is consistently among the national leaders in attracting external funding.
 Unigene Laboratories, Inc. has developed a proprietary amidation process capable of producing peptide hormones for the treatment of a variety of diseases and disorders including osteoporosis, diabetes and hypertension.
 -0- 11/11/92
 /CONTACT: Dr. Ronald S. Levy, vice president of Unigene Laboratories, 201-882-0860/
 (UGNE) CO: Unigene Laboratories, Inc. ST: New Jersey IN: MTC SU:


CK-PS -- NY043 -- 9743 11/11/92 12:42 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 11, 1992
Words:467
Previous Article:CALVERT SOCIAL INVESTMENT FUND CELEBRATES 10-YEAR ANNIVERSARY AND RECORD GROWTH
Next Article:METROPOLITAN FINANCIAL HIRES JONES
Topics:


Related Articles
UNIGENE PEPTIDE APPEARS TO BUILD BONE IN RATS; U.S. PATENT FILED FOR OSTEOPOROSIS PILL
UNIGENE'S OSTEOPOROSIS PILL EXCEEDS PERFORMANCE Target In All Subjects In Latest Phase 1 Clinical Trial
UNIGENE IND ALLOWED BY FDA; PHASE III TRIALS FOR OSTEOPOROSIS PRODUCT TO BEGIN SHORTLY
Unigene Announces Breakthrough in Production of Osteoporosis Drug
Unigene and Warner-Lambert Finalize Agreement to Develop New Treatment for Osteoporosis
Unigene Receives First Payments from Warner-Lambert for Osteoporosis Product
Unigene Receives Notice of Allowance for Key U.S. Patent for Oral Delivery of Calcitonin for Osteoporosis Treatment
Unigene Awarded New U.S. Patent on Manufacturing Process for Osteoporosis Product
Unigene Receives $3 Million from Warner-Lambert - Achieves Additional Benchmarks In Development Of Oral Osteoporosis Product -.
Unigene Announces Distribution Partner for Injectable Calcitonin Product; Strakan Ltd. to Market in U.K. and Ireland.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters